No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CA Stock MarketDetailed Quotes
BCT BriaCell Therapeutics Corp
- 0.930
- -0.210-18.42%
15min DelayMarket Closed Jul 22 16:00 ET
17.00MMarket Cap-1823P/E (TTM)
1.040High0.860Low143.73KVolume1.040Open1.140Pre Close132.08KTurnover10.29052wk High1.10%Turnover Ratio18.28MShares0.86052wk Low-0.51EPS TTM12.13MFloat Cap672.750Historical HighLossP/E (Static)13.04MShs Float0.860Historical Low-1.715EPS LYR15.79%Amplitude--Dividend TTM-2.09P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BriaCell Quadruples Progression Free Survival (PFS) in Patient With "Eye-Bulging" Metastatic Breast Cancer
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3Significant reduction of "Eye-Bulging" metastatic breast cancer tumor was
Canada Net Change Percentage Gainers & Losers
GAINERS COMPANY SYMBOL LAST CHANGE PERCENT VOLUME ------- ------ ---- ------ ------- ------ Loop Energ
10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Dru
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
Comments
BriaCell Quadruples Progression-Free Survival in Metastatic Breast Cancer Patient.
The field of oncology has witnessed numerous advancements over the years, yet metastatic breast cancer continues to pose challenges. However, recent developments reported by BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) offer a glimmer of hope. The clinical-stage biotechnology company, known for its innovative immunot...
The field of oncology has witnessed numerous advancements over the years, yet metastatic breast cancer continues to pose challenges. However, recent developments reported by BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) offer a glimmer of hope. The clinical-stage biotechnology company, known for its innovative immunot...
Read more
Heat List
CA
Overall
Symbol
Latest Price
%Chg